TRAVERE THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$130M
↑+73.4% +$55Mvs FY2024 (Q4)
Gross Profit
$127M
↑+76.0% +$55Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $130M | $75M |
| COGS | $3M | $3M |
| Gross Profit | $127M | $72M |
| R&D | $58M | $62M |
| SG&A | $102M | $70M |
| D&A | $18M | $12M |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · TVTX · Comparing FY2025 (Q4) vs FY2024 (Q4)